xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05973487</url>
    </required_header>
    <id_info>
      <org_study_id>TSCAN-002</org_study_id>
      <nct_id>NCT05973487</nct_id>
    </id_info>
    <brief_title>A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors</brief_title>
    <official_title>A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>TScan Therapeutics, Inc.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>TScan Therapeutics, Inc.</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        TScan Therapeutics is developing cellular therapies across multiple solid tumors in which&#xD;
        autologous participant-derived T cells are engineered to express a T cell receptor that&#xD;
        recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA)&#xD;
        molecules.&#xD;
  &#xD;
        This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the&#xD;
        safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies&#xD;
        and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally&#xD;
        advanced, metastatic solid tumors disease.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Participants will be screened in a separate screening study, TSCAN-003 (NCT05812027), to&#xD;
        assess their HLA type, tumor-associated antigen (TAA) expression and loss of heterozygosity&#xD;
        (LOH) status. The results of these tests will be used to determine initial eligibility in&#xD;
        this study.&#xD;
  &#xD;
        Depending on the genetic type, participants will be assigned to one of the following study&#xD;
        groups:&#xD;
  &#xD;
        Monotherapy:&#xD;
  &#xD;
          -  Cohort A: TSC-204-A0201 targeting MAGE-A1 on HLA-A*02:01&#xD;
  &#xD;
          -  Cohort B: TSC-204-C0702 targeting MAGE-A1 on HLA-C*07:02&#xD;
  &#xD;
          -  Cohort C: TSC-200-A0201 targeting HPV16 E7 on HLA-A*02:01&#xD;
  &#xD;
        T-Plex Combination:&#xD;
  &#xD;
          -  Cohort AB: TSC-204-A0201 + TSC-204-C0702&#xD;
  &#xD;
          -  Cohort BC: TSC-204-A0201 + TSC-200-A0201&#xD;
  &#xD;
          -  Cohort AC: TSC-204-C0702 + TSC-200-A0201&#xD;
  &#xD;
        Participants will undergo leukapheresis to collect cells to manufacture the TCR-T products.&#xD;
        They will then undergo lymphodepletion and receive one or two doses of the TCR-T cell therapy&#xD;
        product as a monotherapy or part of a combination of TCR-Ts (referred to as T-Plex&#xD;
        combinations in this study).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 30, 2023</start_date>
    <completion_date type="Anticipated">December 30, 2026</completion_date>
    <primary_completion_date type="Anticipated">December 30, 2026</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Evaluate the safety of monotherapy and T- Plex combination TCR-Ts</measure>
      <time_frame>28 days</time_frame>
      <description>Number of subjects with dose limiting toxicities (DLT)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Determine the recommended phase 2 dose of monotherapy and T- Plex combination TCR-Ts</measure>
      <time_frame>Up to 12 months</time_frame>
      <description>Frequency and severity of DLTs, AEs and SAEs</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Investigate preliminary anti-tumor activity of monotherapy and T- Plex combination TCR-Ts</measure>
      <time_frame>Up to 12 months</time_frame>
      <description>Response Evaluation Criteria In Solid Tumors RECIST 1.1</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Investigate the feasibility of repeat dosing of monotherapy and T- Plex combination TCR-Ts</measure>
      <time_frame>Up to 12 months</time_frame>
      <description>Frequency and severity of DLTs, AEs and SAEs</description>
    </secondary_outcome>
    <other_outcome>
      <measure>To measure the persistence of T-Plex TCR-T cells in the peripheral blood with single and repeat doses</measure>
      <time_frame>Up to 24 months</time_frame>
      <description>Percentage of TCR-T cells in the peripheral blood after single and repeat doses</description>
    </other_outcome>
    <other_outcome>
      <measure>To measure the infiltration of T-Plex TCR-T cells into tumors in post-treatment biopsies</measure>
      <time_frame>Up to 24 months</time_frame>
      <description>Percentage of TCR-T cells in the tumor after single and repeat doses</description>
    </other_outcome>
    <other_outcome>
      <measure>To measure the immune activation markers in the tumor after single and repeated doses</measure>
      <time_frame>Up to 24 months</time_frame>
      <description>Status of immune activation markers in the tumor after single and repeat doses</description>
    </other_outcome>
    <number_of_arms>6</number_of_arms>
    <enrollment type="Anticipated">100</enrollment>
    <condition>Head and Neck Cancer</condition>
    <condition>Cervical Cancer</condition>
    <condition>Non-small Cell Carcinoma</condition>
    <condition>Melanoma</condition>
    <condition>Ovarian Cancer</condition>
    <condition>Anogenital Cancers</condition>
    <condition>HPV - Anogenital Human Papilloma Virus Infection</condition>
    <condition>HPV-Related Cervical Carcinoma</condition>
    <condition>HPV-Related Carcinoma</condition>
    <condition>HPV-Related Squamous Cell Carcinoma</condition>
    <condition>HPV-Related Malignancy</condition>
    <condition>HPV-Related Adenocarcinoma</condition>
    <condition>HPV Positive Oropharyngeal Squamous Cell Carcinoma</condition>
    <condition>HPV-Related Adenosquamous Carcinoma</condition>
    <condition>HPV-Associated Vaginal Adenocarcinoma</condition>
    <condition>HPV-Related Endocervical Adenocarcinoma</condition>
    <condition>HPV-Related Anal Squamous Cell Carcinoma</condition>
    <condition>HPV-Related Verrucous Carcinoma</condition>
    <condition>HPV-Related Penile Squamous Cell Carcinoma</condition>
    <condition>HPV-Related Vulvar Squamous Cell Carcinoma</condition>
    <condition>HPV Positive Rectal Squamous Cell Carcinoma</condition>
    <arm_group>
      <arm_group_label>Monotherapy Cohort A</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TSC-204-A0201</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Monotherapy Cohort B</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TSC-204-C0702</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Monotherapy Cohort C</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TSC-200-A0201</description>
    </arm_group>
    <arm_group>
      <arm_group_label>T-Plex Combination Cohort A + B</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TSC-204-A0201 and TSC-204-C0702</description>
    </arm_group>
    <arm_group>
      <arm_group_label>T-Plex Combination Cohort B + C</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TSC-204-C0702 and TSC-200-A0201</description>
    </arm_group>
    <arm_group>
      <arm_group_label>T-Plex Combination Cohort A + C</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>TSC-204-A0201 and TSC-200-A0201</description>
    </arm_group>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>TSC-204-A0201</intervention_name>
      <description>Escalating doses of TSC-204-A0201 as a monotherapy</description>
      <arm_group_label>Monotherapy Cohort A</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>TSC-204-C0702</intervention_name>
      <description>Escalating doses of TSC-204-C0702 as a monotherapy</description>
      <arm_group_label>Monotherapy Cohort B</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>TSC-200-A0201</intervention_name>
      <description>Escalating doses of TSC-200-A0201 as a monotherapy</description>
      <arm_group_label>Monotherapy Cohort C</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>TSC-204-A0201 + TSC-204-C0702</intervention_name>
      <description>Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702</description>
      <arm_group_label>T-Plex Combination Cohort A + B</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>TSC-204-A0201 + TSC-200-A0201</intervention_name>
      <description>Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201</description>
      <arm_group_label>T-Plex Combination Cohort B + C</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>TSC-204-A0201 + TSC-200-A0201</intervention_name>
      <description>Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201</description>
      <arm_group_label>T-Plex Combination Cohort A + C</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Must be at least 18 years.&#xD;
  &#xD;
            2. Locally advanced (unresectable) or metastatic solid tumor for which there are no&#xD;
               available curative treatment options, after failure of the standard of care systemic&#xD;
               therapies for that particular indication.&#xD;
  &#xD;
            3. Any solid tumor, including but not limited to non-nasopharyngeal head and neck cancer,&#xD;
               non-small cell lung cancer, cutaneous melanoma, cervical cancer, ovarian cancer, anal&#xD;
               cancer and genital cancers.&#xD;
  &#xD;
            4. Participants must express one of the following HLA types, as assessed by a qualified&#xD;
               genomics assay in screening study TSCAN-003: HLA-C*07:02, HLA-A*02:01 and HLA-C*07:02&#xD;
               plus HLA-A*02:01&#xD;
  &#xD;
            5. Tumor must express MAGE-A1 and/or HPV16-E7 as assessed by a qualified IHC or RNA-ISH&#xD;
               performed in the last 6 months in screening study TSCAN-003 (NCT05812027).&#xD;
  &#xD;
            6. Eastern Cooperative Oncology Group (ECOG) Performance status 0-1 at screening.&#xD;
  &#xD;
            7. Participants must be able to understand and be willing to give informed consent;&#xD;
               decision-impaired adults may consent with their legally authorized representative.&#xD;
  &#xD;
            8. At least 1 measurable lesion per modified Response Evaluation Criteria in Solid Tumors&#xD;
               (RECIST) v1.1.&#xD;
  &#xD;
            9. Adequate bone marrow and organ function.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Medical or psychological conditions that would make the participant unsuitable&#xD;
               candidate for cell therapy at the discretion of the PI.&#xD;
  &#xD;
            2. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,&#xD;
               cardiac arrhythmia requiring antiarrhythmic or procedure, or other clinically&#xD;
               significant cardiac disease within 12 months of enrollment&#xD;
  &#xD;
            3. History of stroke or transient ischemic attack (TIA) within 12 months of enrollment&#xD;
  &#xD;
            4. Systemic corticosteroid therapy &gt;10 mg of prednisone daily or equivalent within 7 days&#xD;
               of enrollment&#xD;
  &#xD;
            5. History of severe hypersensitivity to fludarabine or cyclophosphamide or study product&#xD;
               excipients including human serum albumin, Cryostor (DMSO or Dextran 40), or&#xD;
               Plasma-Lyte.&#xD;
  &#xD;
            6. Untreated or symptomatic central nervous system (CNS) metastases or cytology proven&#xD;
               carcinomatous meningitis.&#xD;
  &#xD;
            7. Concurrent receipt of another anti-cancer therapy.&#xD;
  &#xD;
            8. Presence of fungal, bacterial, viral, or other infection requiring anti-microbials for&#xD;
               management.&#xD;
  &#xD;
            9. Tumors that have HLA LOH using a central lab clinical trial assay of HLAs addressed by&#xD;
               the monotherapy and/or T-Plex combination TCR-Ts in the protocol and have no available&#xD;
               TCR-T options for intact HLAs in the participant's tumor.&#xD;
  &#xD;
           10. Participants who regularly require supplemental oxygen.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Debora Barton, MD</last_name>
      <role>Study Director</role>
      <affiliation>TScan Therapeutics</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Marlyane Motta, BS</last_name>
      <phone>857-399-9887</phone>
      <email>mmotta@tscan.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>OncoBay Clinical CRO</last_name>
      <phone>843-321-8490</phone>
      <email>oncobaysites@oncobay.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>HonorHealth Research and Innovation Institute</name>
        <address>
          <city>Scottsdale</city>
          <state>Arizona</state>
          <zip>85258</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Justin Moser, MD</last_name>
        <phone>480-323-1364</phone>
        <email>clinicaltrials@honorhealth.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Memorial Healthcare System</name>
        <address>
          <city>Hollywood</city>
          <state>Florida</state>
          <zip>33021</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Brian Pico, MD</last_name>
        <phone>954-265-1847</phone>
        <email>bpico@mhs.net</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>University of North Carolina at Chapel Hill</name>
        <address>
          <city>Chapel Hill</city>
          <state>North Carolina</state>
          <zip>27599</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Jared Weiss, MD</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Providence Cancer Institute Franz Clinic</name>
        <address>
          <city>Portland</city>
          <state>Oregon</state>
          <zip>97213</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Rom Leidner, MD</last_name>
        <phone>503-215-5696</phone>
        <email>rom.leidner@providence.org</email>
      </contact>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>July 25, 2023</study_first_submitted>
    <study_first_submitted_qc>August 1, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 3, 2023</study_first_posted>
    <last_update_submitted>September 7, 2023</last_update_submitted>
    <last_update_submitted_qc>September 7, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 8, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>HPV16 E7</keyword>
    <keyword>MAGE-A1</keyword>
    <keyword>TSC-204-A0201</keyword>
    <keyword>TSC-204-C0702</keyword>
    <keyword>TSC-200-A0201</keyword>
    <keyword>TCR-T Therapy</keyword>
    <keyword>Cell Therapy</keyword>
    <keyword>Immunotherapy</keyword>
    <keyword>TScan Therapeutics</keyword>
    <keyword>TSCAN-002</keyword>
    <keyword>TSCAN-003</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Papillomavirus Infections</mesh_term>
      <mesh_term>Carcinoma</mesh_term>
      <mesh_term>Carcinoma, Squamous Cell</mesh_term>
      <mesh_term>Adenocarcinoma</mesh_term>
      <mesh_term>Carcinoma, Verrucous</mesh_term>
      <mesh_term>Papilloma</mesh_term>
      <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
      <mesh_term>Carcinoma, Adenosquamous</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Trans-sodium crocetinate</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05973487
  org study id: TSCAN-002
  nct id: NCT05973487
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  TScan Therapeutics is developing cellular therapies across multiple solid tumors in which
        autologous participant-derived T cells are engineered to express a T cell receptor that
        recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA)
        molecules.
  
        This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the
        safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies
        and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally
        advanced, metastatic solid tumors disease.
  Participants will be screened in a separate screening study, TSCAN-003 (NCT05812027), to
        assess their HLA type, tumor-associated antigen (TAA) expression and loss of heterozygosity
        (LOH) status. The results of these tests will be used to determine initial eligibility in
        this study.
  
        Depending on the genetic type, participants will be assigned to one of the following study
        groups:
  
        Monotherapy:
  
          -  Cohort A: TSC-204-A0201 targeting MAGE-A1 on HLA-A*02:01
  
          -  Cohort B: TSC-204-C0702 targeting MAGE-A1 on HLA-C*07:02
  
          -  Cohort C: TSC-200-A0201 targeting HPV16 E7 on HLA-A*02:01
  
        T-Plex Combination:
  
          -  Cohort AB: TSC-204-A0201 + TSC-204-C0702
  
          -  Cohort BC: TSC-204-A0201 + TSC-200-A0201
  
          -  Cohort AC: TSC-204-C0702 + TSC-200-A0201
  
        Participants will undergo leukapheresis to collect cells to manufacture the TCR-T products.
        They will then undergo lymphodepletion and receive one or two doses of the TCR-T cell therapy
        product as a monotherapy or part of a combination of TCR-Ts (referred to as T-Plex
        combinations in this study).
  allocation: Non-Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Evaluate the safety of monotherapy and T- Plex combination TCR-Ts
  time frame: 28 days
  description: Number of subjects with dose limiting toxicities (DLT)
  measure: Determine the recommended phase 2 dose of monotherapy and T- Plex combination TCR-Ts
  time frame: Up to 12 months
  description: Frequency and severity of DLTs, AEs and SAEs
  measure: Investigate preliminary anti-tumor activity of monotherapy and T- Plex combination TCR-Ts
  time frame: Up to 12 months
  description: Response Evaluation Criteria In Solid Tumors RECIST 1.1
  measure: Investigate the feasibility of repeat dosing of monotherapy and T- Plex combination TCR-Ts
  time frame: Up to 12 months
  description: Frequency and severity of DLTs, AEs and SAEs
  measure: To measure the persistence of T-Plex TCR-T cells in the peripheral blood with single and repeat doses
  time frame: Up to 24 months
  description: Percentage of TCR-T cells in the peripheral blood after single and repeat doses
  measure: To measure the infiltration of T-Plex TCR-T cells into tumors in post-treatment biopsies
  time frame: Up to 24 months
  description: Percentage of TCR-T cells in the tumor after single and repeat doses
  measure: To measure the immune activation markers in the tumor after single and repeated doses
  time frame: Up to 24 months
  description: Status of immune activation markers in the tumor after single and repeat doses
  arm group label: Monotherapy Cohort A
  arm group type: Experimental
  description: TSC-204-A0201
  arm group label: Monotherapy Cohort B
  arm group type: Experimental
  description: TSC-204-C0702
  arm group label: Monotherapy Cohort C
  arm group type: Experimental
  description: TSC-200-A0201
  arm group label: T-Plex Combination Cohort A + B
  arm group type: Experimental
  description: TSC-204-A0201 and TSC-204-C0702
  arm group label: T-Plex Combination Cohort B + C
  arm group type: Experimental
  description: TSC-204-C0702 and TSC-200-A0201
  arm group label: T-Plex Combination Cohort A + C
  arm group type: Experimental
  description: TSC-204-A0201 and TSC-200-A0201
  intervention type: Biological
  intervention name: TSC-204-A0201
  description: Escalating doses of TSC-204-A0201 as a monotherapy
  arm group label: Monotherapy Cohort A
  intervention type: Biological
  intervention name: TSC-204-C0702
  description: Escalating doses of TSC-204-C0702 as a monotherapy
  arm group label: Monotherapy Cohort B
  intervention type: Biological
  intervention name: TSC-200-A0201
  description: Escalating doses of TSC-200-A0201 as a monotherapy
  arm group label: Monotherapy Cohort C
  intervention type: Biological
  intervention name: TSC-204-A0201 + TSC-204-C0702
  description: Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
  arm group label: T-Plex Combination Cohort A + B
  intervention type: Biological
  intervention name: TSC-204-A0201 + TSC-200-A0201
  description: Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
  arm group label: T-Plex Combination Cohort B + C
  intervention type: Biological
  intervention name: TSC-204-A0201 + TSC-200-A0201
  description: Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
  arm group label: T-Plex Combination Cohort A + C
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Debora Barton, MD
  role: Study Director
  affiliation: TScan Therapeutics
  last name: Marlyane Motta, BS
  phone: 857-399-9887
  email: mmotta@tscan.com
  last name: OncoBay Clinical CRO
  phone: 843-321-8490
  email: oncobaysites@oncobay.com
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  country: United States
  responsible party type: Sponsor
  mesh term: Papillomavirus Infections
  mesh term: Carcinoma
  mesh term: Carcinoma, Squamous Cell
  mesh term: Adenocarcinoma
  mesh term: Carcinoma, Verrucous
  mesh term: Papilloma
  mesh term: Squamous Cell Carcinoma of Head and Neck
  mesh term: Carcinoma, Adenosquamous
  mesh term: Trans-sodium crocetinate
  sharing ipd: No